Table 2.
Solicited Local Adverse Events (AEs) Following First and Second Dose Vaccination With Standard Doses of Ad26.ZEBOV (Ad26) and MVA-BN-Filo (MVA)
| AE, Severity | MVA (n = 60) |
Ad26 (n = 59) |
Placebo (n = 24) |
|---|---|---|---|
| Any | |||
| Any | 48 (80) | 38 (64) | 11 (46) |
| Grade 1 | 40 (67) | 32 (54) | 10 (42) |
| Grade 2 | 8 (13) | 5 (9) | 1 (4) |
| Grade 3 | 0 | 1 (2) | 0 |
| Injection site pain | |||
| Any | 47 (78) | 37 (63) | 8 (33) |
| Grade 1 | 39 (65) | 32 (54) | 8 (33) |
| Grade 2 | 8 (13) | 4 (7) | 0 |
| Grade 3 | 0 | 1 (2) | 0 |
| Injection site pruritusa | |||
| Any | 10 (17) | 10 (17) | 2 (8) |
| Grade 1 | 10 (17) | 9 (15) | 2 (8) |
| Grade 2 | 0 | 1 (2) | 0 |
| Injection site warmth | |||
| Any | 13 (22) | 18 (31) | 6 (25) |
| Grade 1 | 13 (22) | 15 (25) | 5 (21) |
| Grade 2 | 0 | 2 (3) | 1 (4) |
| Grade 3 | 0 | 1 (2) | 0 |
Data are no. (%) of doses and reflect pooled first and second dose vaccination data from all 4 vaccination regimens.
aNo grade 3 AEs were reported.